Latest News & Features
Asia
The regulatory and IP environment in China is shifting at a rapid pace, bringing new measures, guiding cases, and compliance hurdles. This session provides a high-level overview of the past year’s critical changes and what life sciences companies must anticipate on the horizon. 24 May 2026
Unified Patent Court
Managing parallel revocation actions requires a meticulous approach to forum choice and sequencing. This presentation unpacks the lessons learned from the first year of simultaneous EPO and UPC proceedings, offering tactics to leverage opportunities and minimise cross-border risks. 23 May 2026
Americas
A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival. 22 May 2026
Americas
How can innovators secure reliable protection across diagnostics, genetics, and AI-integrated devices while navigating Section 101 and 112 pitfalls? This comprehensive panel addresses strategies to clear fundamental patentability hurdles amid shifting court decisions and USPTO guidelines. 22 May 2026
Americas
European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration. 21 May 2026
Europe
The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries. 21 May 2026
Americas
The rapid evolution of CRISPR and base editing brings transformative medical potential alongside deeply complex IP and licensing hurdles. This session explores how companies can balance innovation with risk mitigation in a crowded and highly contested precision medicine landscape. 21 May 2026
Asia
Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives. 20 May 2026
Americas
The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies. 20 May 2026
Americas
The influx of biosimilars and generics requires innovator companies and challengers alike to continually refine their litigation tactics. This panel dissects current trends in Hatch-Waxman and BPCIA frameworks, providing a roadmap for defending franchises and navigating market entry. 20 May 2026